Content about Recombinant proteins

June 20, 2011

Last month, the Food and Drug Administration approved Tradjenta (linagliptin), an oral Type 2 diabetes drug made by German drug maker Boehringer Ingelheim and Indianapolis-based Eli Lilly. The drug belongs to the class known as dipeptidyl peptidase-4 inhibitors, which also includes Merck’s Januvia (sitagliptin). With diabetes affecting some 26 million Americans and growing rapidly, Drug Store News spoke with Wa’el Hashad, BI’s VP cardiovascular and metabolic disorders marketing, about what the approval of Tradjenta means for the diabetes market.


June 9, 2011

Patients with Type 1 diabetes using an insulin product made by Eli Lilly can store it in their pumps for longer periods of time, while children using it have additional options, thanks to a labeling change approved Wednesday by the Food and Drug Administration.

INDIANAPOLIS — Patients with Type 1 diabetes using an insulin product made by Eli Lilly can store it in their pumps for longer periods of time, while children using it have additional options, thanks to a labeling change approved Wednesday by the Food and Drug Administration.

June 2, 2011

A company that develops insulin-pump technology without tubing, such as the OmniPod insulin management system, has acquired a durable medical equipment distributor that specializes in direct-to-consumer sales of diabetes supplies.

BEDFORD, Mass. — A company that develops insulin-pump technology without tubing, such as the OmniPod insulin management system, has acquired a durable medical equipment distributor that specializes in direct-to-consumer sales of diabetes supplies.

May 31, 2011

New results from a late-stage clinical trial of a Sanofi drug for Type 2 diabetes indicated that the drug can reduce blood sugar in patients without increasing the risk of causing the blood sugar levels to dip too low, the French drug maker said Tuesday.

PARIS — New results from a late-stage clinical trial of a Sanofi drug for Type 2 diabetes indicated that the drug can reduce blood sugar in patients without increasing the risk of causing the blood sugar levels to dip too low, the French drug maker said Tuesday.

March 24, 2011

Novo Nordisk said new data showed that its basal insulin analog is just as effective as human basal insulin in Type 1 diabetes patients ages 2 to 5 years.

COPENHAGEN — Novo Nordisk said new data showed that its basal insulin analog is just as effective as human basal insulin in Type 1 diabetes patients ages 2 to 5 years.

March 14, 2011

A drug maker focused on development and commercialization of diabetes treatments unveiled its accelerating clinical development plans of two drug candidates.

DANBURY, Conn. — A drug maker focused on development and commercialization of diabetes treatments unveiled its accelerating clinical development plans of two drug candidates.

Biodel said BIOD-105 and BIOD-107, known as ultra rapid-acting insulins, are designed to result in more rapid insulin action, compared with currently marketed mealtime insulin analogs.

January 19, 2011

An insulin pen for children made by Novo Nordisk has won a design award, the company said Wednesday.

CRAWLEY, England — An insulin pen for children made by Novo Nordisk has won a design award, the company said Wednesday.

The Danish drug maker won the 2010 Good Design Award from the Chicago Athenaeum Museum of Architecture and Design and the European Centre for Architecture, Art, Design and Urban Studies for its NovoPen Echo, used to treat Type 1 diabetes. The annual award, which the two organizations have given since 1950, are the oldest and among the most coveted for design and innovation, Novo Nordisk said.

January 11, 2011

U.S. drug maker Eli Lilly and German drug maker Boehringer Ingelheim will collaborate to develop drugs for diabetes, the companies said Tuesday.

INDIANAPOLIS — U.S. drug maker Eli Lilly and German drug maker Boehringer Ingelheim will collaborate to develop drugs for diabetes, the companies said Tuesday.

The agreement centers around investigative drugs currently in mid- to late-stage clinical development, including two oral drugs made by BI, BI10773 and linagliptin, and two basal insulin analogues made by Lilly, LY2605541 and LY2963016. The deal also includes options to develop and commercialize a Lilly monoclonal antibody.

January 3, 2011

This past year saw a lower-than-usual number of new drugs approved by the Food and Drug Administration, due in part to delays at the agency, according to published reports.

NEW YORK — This past year saw a lower-than-usual number of new drugs approved by the Food and Drug Administration, due in part to delays at the agency, according to published reports.

The Wall Street Journal reported that 21 new drugs were approved through the year, compared with 25 in 2009 and 24 in 2008. The lag came in part due to stricter safety regulations, the newspaper reported.

December 21, 2010

A biopharmaceutical company exclusively will develop and commercialize oral formulations of a drug maker's insulins.

PRINCETON, N.J. — A biopharmaceutical company exclusively will develop and commercialize oral formulations of a drug maker's insulins.

Emisphere will be paid $57.5 million in potential product development and sales milestone payments by Novo Nordisk — of which $5 million dollars will be payable upon signing — as well as royalties on sales. Further financial details of the agreement were not disclosed.

December 9, 2010

Combining a diabetes drug marketed by Eli Lilly and Amylin Pharmaceuticals controls blood sugar and promotes weight loss more than insulin alone, according to a new study.

CHAPEL HILL, N.C. — Combining a diabetes drug marketed by Eli Lilly and Amylin Pharmaceuticals controls blood sugar and promotes weight loss more than insulin alone, according to a new study.

November 2, 2010

The Food and Drug Administration has turned down an application for an insulin product made...

DANBURY, Conn. The Food and Drug Administration has turned down an application for an insulin product made by Biodel, Biodel said.

 

The drug maker announced that it received a complete response letter from the FDA for Linjeta (human insulin [rDNA origin]) for the treatment of Type 1 and Type 2 diabetes.

 

 

November 2, 2010

The CEO of drug maker Eli Lilly has called for a “wave of invention” to...

CLEVELAND The CEO of drug maker Eli Lilly has called for a “wave of invention” to combat diabetes.

Speaking at the Cleveland Clinic Medical Innovation Summit, John Lechleiter said breakthroughs against the disease are needed as urgently today as a century ago, noting that the disease could create a “health and economic time bomb,” as 1-in-3 Americans are forecasted to have the disease by 2050.

 

October 17, 2010

Pfizer has entered the world of biosimilars through a deal with India-based Biocon to distribute...

NEW YORK Pfizer has entered the world of biosimilars through a deal with India-based Biocon to distribute versions of insulin and insulin analog products around the world, the companies said Monday.

 

September 30, 2010

UltiMed, a company that makes insulin-delivery devices, has named a new executive....

ST. PAUL, Minn. UltiMed, a company that makes insulin-delivery devices, has named a new executive.

 

The company announced the appointment of Brahim Zabeli as VP diabetes care for the U.S. market. In the new role, Zabeli will manage commercial activity, including sales, marketing and customer service.

 

 

Zabeli previously worked as director of trade and managed markets for medical supply company Becton, Dickinson & Co.

 

September 19, 2010

An injected insulin made by French drug maker Sanofi-Aventis provided further reduction of blood sugar...

PARIS An injected insulin made by French drug maker Sanofi-Aventis provided further reduction of blood sugar in patients with Type 2 diabetes when added to oral diabetes drugs, according to a study presented at a medical conference in Sweden.

August 31, 2010

A specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes...

August 29, 2010

Novo Nordisk has launched a mobile dosing app for healthcare professionals that prescribe the drug...

PRINCETON, N.J. Novo Nordisk has launched a mobile dosing app for healthcare professionals that prescribe the drug maker's insulin products.

NovoDose, which is available for download on iTunes, allows physicians to select the type of insulin they want to research and review suggested guidelines for dosing, titration and even blood glucose goals for their patients. The app also provides important safety information on the products, and only those who self-identify as healthcare professionals can download the app.

August 15, 2010

The Juvenile Diabetes Research Foundation has expanded its artifical pancreas program with an initiative that...

June 24, 2010

French drug maker Sanofi-Aventis has made a deal with U.S. drug maker Metabolex to license...

June 21, 2010

Generex Biotechnology Corp. will be among the companies exhibiting at an upcoming American Diabetes Association...

June 13, 2010

Teva Pharmaceutical Industries has invested $11.9 million in Andromeda Biotech, a company that develops diabetes...

May 2, 2010

Novo Nordisk is asking diabetics to show off how they flex -- their insulin pens....

February 10, 2010

A specialty biopharmaceutical company focused on endocrine disorder treatments will present results of two phase...

January 13, 2010

Novo Nordisk has started an early-stage clinical trial in the United Kingdom of an investigational...